Today’s Market Runner: Is Puma Biotechnology Inc’s Fuel For Real? The Stock Just Increased Again

Today's Market Runner: Is Puma Biotechnology Inc's Fuel For Real? The Stock Just Increased Again

The stock of Puma Biotechnology Inc (NYSE:PBYI) is a huge mover today! The stock increased 4.75% or $2.1 on November 23, hitting $46.3. About 378,600 shares traded hands. Puma Biotechnology Inc (NYSE:PBYI) has risen 36.26% since April 22, 2016 and is uptrending. It has outperformed by 30.85% the S&P500.
The move comes after 8 months positive chart setup for the $1.72B company. It was reported on Nov, 24 by Barchart.com. We have $50.00 PT which if reached, will make NYSE:PBYI worth $137.60 million more.

Analysts await Puma Biotechnology Inc (NYSE:PBYI) to report earnings on March, 6. They expect $-2.02 EPS, down 6.32% or $0.12 from last year’s $-1.9 per share. After $-2.02 actual EPS reported by Puma Biotechnology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage

Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Citigroup initiated Puma Biotechnology Inc (NYSE:PBYI) on Thursday, September 3 with “Neutral” rating. The stock of Puma Biotechnology Inc (NYSE:PBYI) earned “Buy” rating by UBS on Monday, April 11. The rating was initiated by JP Morgan on Thursday, August 27 with “Overweight”. The stock of Puma Biotechnology Inc (NYSE:PBYI) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. On Tuesday, March 29 the stock rating was maintained by JP Morgan with “Overweight”. Stifel Nicolaus upgraded it to “Buy” rating and $88 target price in Wednesday, September 21 report. The stock has “Buy” rating given by Citigroup on Tuesday, March 29. Credit Suisse maintained it with “Outperform” rating and $50 target price in Tuesday, March 29 report. RBC Capital Markets downgraded Puma Biotechnology Inc (NYSE:PBYI) rating on Tuesday, March 29. RBC Capital Markets has “Sector Perform” rating and $36 price target. The rating was upgraded by Citigroup to “Buy” on Monday, December 14.

According to Zacks Investment Research, “Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.”

Insitutional Activity: The institutional sentiment increased to 1.49 in Q2 2016. Its up 0.28, from 1.21 in 2016Q1. The ratio improved, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
Thrivent Fin For Lutherans holds 20,260 shares or 0% of its portfolio. Nationwide Fund Advisors holds 16,108 shares or 0% of its portfolio. Huntington Comml Bank, a Ohio-based fund reported 7 shares. Everpoint Asset Mngmt Ltd Liability Company last reported 450,000 shares in the company. Aberdeen Asset Mngmt Public Limited Liability Uk has 36,220 shares for 0% of their US portfolio. Dai Ichi Life Insurance Ltd holds 0.03% or 28,571 shares in its portfolio. Guggenheim Lc, a Illinois-based fund reported 11,555 shares. Canada Pension Plan Investment Board reported 10,900 shares or 0% of all its holdings. D E Shaw & owns 135,727 shares or 0.01% of their US portfolio. Schwab Charles Mgmt holds 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 105,022 shares. Eaton Vance Mgmt has 142,000 shares for 0.01% of their US portfolio. Rock Springs Cap Mgmt Lp has invested 0.07% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI). Tekla Capital Mngmt Ltd Co holds 0.32% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 260,200 shares. Weatherbie Limited Liability Com owns 280,985 shares or 1.19% of their US portfolio. Federated Investors Pa holds 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 50,139 shares.

More notable recent Puma Biotechnology Inc (NYSE:PBYI) news were published by: Fool.com which released: “Why Puma Biotechnology Inc. Sold Lower Today” on October 19, 2016, also Fool.com with their article: “Why Puma Biotechnology Inc Roared Higher Today” published on September 20, 2016, Fool.com published: “Why Puma Biotechnology, Inc. Stock Crashed 37% in March” on April 11, 2016. More interesting news about Puma Biotechnology Inc (NYSE:PBYI) were released by: Prnewswire.com and their article: “Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company …” published on October 11, 2016 as well as Fool.com‘s news article titled: “Why Puma Biotechnology, Inc. Stock Soared 65.1% in July” with publication date: August 04, 2016.

PBYI Company Profile

Puma Biotechnology, Inc., incorporated on September 15, 2010, is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment